Barrett's esophagus future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
Created page with "__NOTOC__ {{Barrett's esophagus}} Please help WikiDoc by adding content here. It's easy! Click here to learn about editing. ==References== {{..." |
Pal Manickam (talk | contribs) |
||
| Line 3: | Line 3: | ||
Please help WikiDoc by adding content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | Please help WikiDoc by adding content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | ||
==Overview== | |||
* Biomarkers | |||
# Can not be used to confirm the diagnosis of Barrett´s esophagus. | |||
# Can not be used to predict risk of progression. | |||
# Promissing for the future<ref name="pmid21376940">{{cite journal |author=Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ |title=American Gastroenterological Association medical position statement on the management of Barrett's esophagus |journal=Gastroenterology |volume=140 |issue=3 |pages=1084–91 |year=2011 |month=March |pmid=21376940 |doi=10.1053/j.gastro.2011.01.030 |url=}}</ref>. | |||
* Endoscopic Therapy | |||
# In patients with confirmed high-grade dysplasia with Barrett' esophagus it is more recommended to proceed with endoscopic eradication therapy with radiofrequency ablation (RFA), photodynamic therapy (PDT), or endoscopic mucosal resection (EMR) rather than surveillance. | |||
# In patients who have dysplasia in Barrett's esophagus associated with a visible mucosal irregularity it is recommended to proceed with endoscopic mucosal resection (EMR) to determine the T stage of the neoplasia<ref name="pmid21376940">{{cite journal |author=Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ |title=American Gastroenterological Association medical position statement on the management of Barrett's esophagus |journal=Gastroenterology |volume=140 |issue=3 |pages=1084–91 |year=2011 |month=March |pmid=21376940 |doi=10.1053/j.gastro.2011.01.030 |url=}}</ref>. | |||
==References== | ==References== | ||
Revision as of 01:04, 3 January 2013
|
Barrett's Esophagus Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Barrett's esophagus future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Barrett's esophagus future or investigational therapies |
|
FDA on Barrett's esophagus future or investigational therapies |
|
CDC on Barrett's esophagus future or investigational therapies |
|
Barrett's esophagus future or investigational therapies in the news |
|
Blogs on Barrett's esophagus future or investigational therapies |
|
Risk calculators and risk factors for Barrett's esophagus future or investigational therapies |
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
- Biomarkers
- Can not be used to confirm the diagnosis of Barrett´s esophagus.
- Can not be used to predict risk of progression.
- Promissing for the future[1].
- Endoscopic Therapy
- In patients with confirmed high-grade dysplasia with Barrett' esophagus it is more recommended to proceed with endoscopic eradication therapy with radiofrequency ablation (RFA), photodynamic therapy (PDT), or endoscopic mucosal resection (EMR) rather than surveillance.
- In patients who have dysplasia in Barrett's esophagus associated with a visible mucosal irregularity it is recommended to proceed with endoscopic mucosal resection (EMR) to determine the T stage of the neoplasia[1].
References
- ↑ 1.0 1.1 Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ (2011). "American Gastroenterological Association medical position statement on the management of Barrett's esophagus". Gastroenterology. 140 (3): 1084–91. doi:10.1053/j.gastro.2011.01.030. PMID 21376940. Unknown parameter
|month=ignored (help)